10月17日(路透社) - 默沙东:*Pimicotinib治疗显示出对TGCT患者深度和持久的肿瘤反应,以及对疼痛和功能的持续改善*在14.3个月的中位随访期内,Pimicotinib的整体反应率(ORR)随着时间的推移逐渐增加,从第25周的54%升至76.2%*全球3期Maneuver研究显示在关键次要终点,包括疼痛和功能方面的持续改善*针对市场授权的申请正在中国国家药品监督管理局(NMPA)审查中,并计划在美国及其他市场提交额外申请*更多公司信息:MRCG.DE*
10月17日(路透社) - 默沙东:*Pimicotinib治疗显示出对TGCT患者深度和持久的肿瘤反应,以及对疼痛和功能的持续改善*在14.3个月的中位随访期内,Pimicotinib的整体反应率(ORR)随着时间的推移逐渐增加,从第25周的54%升至76.2%*全球3期Maneuver研究显示在关键次要终点,包括疼痛和功能方面的持续改善*针对市场授权的申请正在中国国家药品监督管理局(NMPA)审查中,并计划在美国及其他市场提交额外申请*更多公司信息:MRCG.DE*
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.